Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : Says FDA Authorises Restart Of COVID-19 Vaccine Trial in U.S.

10/23/2020 | 03:45pm EST

Oct 23 (Reuters) - AstraZeneca PLC:

* FDA AUTHORISES RESTART OF COVID-19 AZD1222 VACCINE US PHASE III TRIA

* FOOD AND DRUG ADMINISTRATION (FDA) AUTHORISED RESTART OF TRIAL IN US

* FDA REVIEWED ALL SAFETY DATA FROM TRIALS GLOBALLY AND CONCLUDED IT WAS SAFE TO RESUME TRIAL. Further company coverage:


© Reuters 2020
All news about ASTRAZENECA PLC
11:22aSerum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11:18aSerum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
10:59aUK regulator set to approve COVID-19 vaccine next week - FT
RE
10:31aIndia's Modi visits key vaccine facilities as COVID-19 cases surge
RE
08:22aUK appoints vaccines minister to oversee COVID inoculations
AQ
08:05aIndia's Modi visits key vaccine facilities as COVID-19 case load surges
RE
03:32aOil prices post weekly gain ahead of OPEC+ meeting
RE
11/27SALESFORCE, DELTA AIR LINES, BEST BU : Stocks That Defined the Week
DJ
11/27Stocks at record high but yields fall, dollar under pressure
RE
11/27Oil prices post weekly gain ahead of OPEC+ meeting
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,5x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,49 $
Last Close Price 103,45 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.14%135 908
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440